Medicinal and Pharmaceutical Chemistry Commons^™

Pcsk9 Inhibitors In Secondary Prevention – An Opportunity For Personalized Therapy, Chase Board, Michael S. Kelly, Michael D. Shapiro, Dave L. Dixon

Pharmacy Faculty Articles and Research

Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death worldwide. Low-density lipoprotein cholesterol (LDL-C) is the primary cause of ASCVD and reducing LDL-C levels with statin therapy significantly reduces ASCVD risk; however, significant residual risk remains. Two monoclonal antibodies (mAbs), alirocumab and evolocumab, that target proprotein convertase subtilisin/kexin-type 9 (PCSK9), reduce LDL-C levels by up to 60% when used in combination with statins and significantly reduce the risk of recurrent ASCVD events in both stable secondary prevention and acute coronary syndrome populations. Pre-specified analyses of recent randomized controlled trials have shed light on how best to prioritize these therapies …